- Home
- FLUX vs BCTX Comparison
FLUX vs BCTX Comparison
Compare FLUX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- BCTX
- Stock Information
- Founded
- FLUX N/A
- BCTX 2014
- Country
- FLUX United States
- BCTX Canada
- Employees
- FLUX N/A
- BCTX N/A
- Industry
- FLUX Industrial Machinery/Components
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- FLUX Miscellaneous
- BCTX Health Care
- Exchange
- FLUX Nasdaq
- BCTX Nasdaq
- Market Cap
- FLUX 33.5M
- BCTX 34.6M
- IPO Year
- FLUX N/A
- BCTX N/A
- Fundamental
- Price
- FLUX $1.71
- BCTX $0.56
- Analyst Decision
- FLUX Strong Buy
- BCTX Strong Buy
- Analyst Count
- FLUX 4
- BCTX 1
- Target Price
- FLUX $9.50
- BCTX $15.00
- AVG Volume (30 Days)
- FLUX 106.1K
- BCTX 2.4M
- Earning Date
- FLUX 02-06-2025
- BCTX 12-16-2024
- Dividend Yield
- FLUX N/A
- BCTX N/A
- EPS Growth
- FLUX N/A
- BCTX N/A
- EPS
- FLUX N/A
- BCTX N/A
- Revenue
- FLUX $63,850,000.00
- BCTX N/A
- Revenue This Year
- FLUX N/A
- BCTX N/A
- Revenue Next Year
- FLUX $13.51
- BCTX N/A
- P/E Ratio
- FLUX N/A
- BCTX N/A
- Revenue Growth
- FLUX N/A
- BCTX N/A
- 52 Week Low
- FLUX $1.55
- BCTX $0.46
- 52 Week High
- FLUX $5.86
- BCTX $5.97
- Technical
- Relative Strength Index (RSI)
- FLUX 40.50
- BCTX 38.43
- Support Level
- FLUX $1.66
- BCTX $0.57
- Resistance Level
- FLUX $1.81
- BCTX $0.66
- Average True Range (ATR)
- FLUX 0.15
- BCTX 0.13
- MACD
- FLUX 0.02
- BCTX -0.05
- Stochastic Oscillator
- FLUX 45.71
- BCTX 0.00
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.